Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter

@article{Cozzi2009DimethyltryptamineAO,
  title={Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter},
  author={Nicholas V Cozzi and Anupama Gopalakrishnan and Lyndsey L Anderson and Joel T. Feih and Alexander T. Shulgin and Paul F. Daley and Arnold E Ruoho},
  journal={Journal of Neural Transmission},
  year={2009},
  volume={116},
  pages={1591-1599}
}
N,N-dimethyltryptamine (DMT) is a potent plant hallucinogen that has also been found in human tissues. When ingested, DMT and related N,N-dialkyltryptamines produce an intense hallucinogenic state. Behavioral effects are mediated through various neurochemical mechanisms including activity at sigma-1 and serotonin receptors, modification of monoamine uptake and release, and competition for metabolic enzymes. To further clarify the pharmacology of hallucinogenic tryptamines, we synthesized DMT, N… Expand
Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes
TLDR
All psychoactive tryptamines are 5-HT2A agonists, but5-HT transporter (SERT) activity may contribute significantly to the pharmacology of certain compounds, and in vitro transporter data confirm structure-activity trends for releasers and uptake inhibitors whereby releasers tend to be structurally smaller compounds. Expand
Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
TLDR
The receptor interaction profiles of the tryptamines predict hallucinogenic effects that are similar to classic serotonergic hallucinogens but also MDMA-like psychoactive properties. Expand
Metabolites of Tryptamine : Endogenous psychedelic neurotransmitters , and N , N dimethyltryptamine ( DMT ) in explaining a new pathway to produce Serotonin , Melatonin and hallucinations
Why naturally occurring psychoactive psychedelics, N,N-dimethyltryptamine (DMT), 5hydroxy-DMT (Bufotenine, HDMT) and 5-Methoxy-DMT (MDMT) occur naturally in the human body has very littleExpand
The role of 5-HT2A, 5-HT2C and mGlu2 receptors in the behavioral effects of tryptamine hallucinogens N,N-dimethyltryptamine and N,N-diisopropyltryptamine in rats and mice
TLDR
The 5-HT2AR likely plays a major role in mediating the effects of two tryptamine hallucinogenic drugs and likely modulate the discriminative stimulus effects of both compounds. Expand
The hallucinogenic world of tryptamines: an updated review
TLDR
A comprehensive update on tryptamine hallucinogens, concerning their historical background, prevalence, patterns of use and legal status, chemistry, toxicokinetics, toxicodynamics and their physiological and toxicological effects on animals and humans is provided. Expand
Noncompetitive Inhibition of Indolethylamine-N-methyltransferase by N,N-Dimethyltryptamine and N,N-Dimethylaminopropyltryptamine
TLDR
The demonstration of noncompetitive mechanisms for INMT inhibition implies the presence of an inhibitory allosteric site, which may illuminate new biochemical pathway(s) underlying the biology of INMT. Expand
Hallucinogen-Like Action of the Novel Designer Drug 25I-NBOMe and Its Effect on Cortical Neurotransmitters in Rats
TLDR
The data from this study suggest that hallucinogenic activity of 25I-NBOMe seems to be related with the increase in extracellular GLU level-mediated via cortical 5-HT2A receptors, and may modulate its effect on neurotransmitters and HTR. Expand
Abuse Liability Profile of Three Substituted Tryptamines
TLDR
DIPT and 5-MeO-DET may have abuse liability similar to known hallucinogens and may be hazardous because high doses produced activity and lethality, but were not similar to those of psychostimulants. Expand
Chapter 15 – Tryptamines
Tryptamines are a diverse group of 5HT2A agonist compounds. The predominant clinical effect produced by tryptamine exposure is hallucinations, mediated by agonism at 5HT2A and 5HT1A receptors.Expand
In vivo imaging of cerebral serotonin transporter and serotonin(2A) receptor binding in 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") and hallucinogen users.
TLDR
Evidence is found that MDMA but not hallucinogen use is associated with changes in the cerebral presynaptic serotonergic transmitter system, and cross-sectional data suggest that subcortical, but not cortical, recovery of SERT binding might take place after several months of MDMA abstinence. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 76 REFERENCES
Hallucinogen-like effects of N,N-dipropyltryptamine (DPT): Possible mediation by serotonin 5-HT1A and 5-HT2A receptors in rodents
TLDR
The effectiveness with which M100907 antagonizes the behavioral actions of DPT strongly suggest that the 5-HT2A receptor is an important site of action for DPT, but the modulatory actions of WAY-100635 also imply a 5- HT1A-mediated component to the actions of this compound. Expand
The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain.
TLDR
The results suggest that some designer drugs strongly act on the central nerve system to the same extent as restricted drugs. Expand
Differential interactions of dimethyltryptamine (DMT) with 5-HT1A and 5-HT2 receptors.
TLDR
DMT has opposing actions on 5-HT receptor subtypes, displaying agonist activity at5-HT1A receptors and antagonist activity at 5- HT2 receptors, and these studies suggest that DMT has antagonistic properties at 4-HT2 receptors. Expand
Interactions of tryptamine derivatives with serotonin transporter species variants implicate transmembrane domain I in substrate recognition.
TLDR
A critical role for TMD I residues is supported in defining shared aspects of SERT substrate and antagonist recognition as well as species-specific recognition of citalopram and mazindol. Expand
Serotonin receptor binding affinities of several hallucinogenic phenylalkylamine and N,N-dimethyltryptamine analogues.
TLDR
The most behaviorally potent analogues examined, DOB, DOM, and 5-methoxy-N,N-dimethyltryptamine, were found to possess rather high affirmities for the 5-HT receptors of the model system. Expand
The serotonin receptor agonist 5-methoxy-N,N-dimethyltryptamine facilitates noradrenaline release from rat spinal cord slices and inhibits monoamine oxidase activity.
TLDR
The results provide evidence for two different effects by which MeODMT reinforces noradrenergic neurotransmission in the rat spinal cord: facilitation of stimulation-evoked Noradrenaline release and inhibition of nor adrenaline metabolism by MAO inhibition. Expand
3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine
TLDR
In the neurotoxicity study of the compounds investigated, only (+)MDA caused a significant loss of 5-HT uptake sites in comparison to saline-treated controls, and their possible relevance to neurotoxicity in this series of MDA congeners is discussed. Expand
The Hallucinogen N,N-Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor Regulator
The sigma-1 receptor is widely distributed in the central nervous system and periphery. Originally mischaracterized as an opioid receptor, the sigma-1 receptor binds a vast number of syntheticExpand
Endogenous psychoactive tryptamines reconsidered: an anxiolytic role for dimethyltryptamine.
TLDR
It is proposed that endogenous DMT interacts with the TA receptor to produce a calm and relaxed mental state, which may suppress, rather than promote, symptoms of psychosis, and amphetamine action at the TA receptors may contribute to the calming effects of amphetamine and related drugs, especially at low doses. Expand
Transmembrane Domain I Contributes to the Permeation Pathway for Serotonin and Ions in the Serotonin Transporter
TLDR
The ability of the D98E mutant to modulate selective aspects of substrate recognition, to perturb ion dependence as well as modify substrate-induced currents, suggests that transmembrane domain I plays a critical role in defining the permeation pathway of biogenic amine transporters. Expand
...
1
2
3
4
5
...